Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells 558 Shares of Company Stock

Posted by George Bondi on Oct 6th, 2026

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) Director Ezra Friedberg sold 558 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $20.72, for a total transaction of $11,561.76. Following the transaction, the director owned 80,484 shares in the company, valued at $1,667,628.48. The trade was a 0.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Up 4.8%

NYSEAMERICAN PTHS traded up $0.98 on Tuesday, hitting $21.48. 42,943 shares of the company were exchanged, compared to its average volume of 30,248. The company has a current ratio of 1.98, a quick ratio of 1.31 and a debt-to-equity ratio of 3.40. The company has a market cap of $82.27 million, a PE ratio of -0.98 and a beta of 3.07. The stock has a fifty day moving average of $24.74 and a 200-day moving average of $25.21. Pelthos Therapeutics Inc. has a 12 month low of $18.19 and a 12 month high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. The company had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. As a group, analysts forecast that Pelthos Therapeutics Inc. will post -15.22 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Oppenheimer dropped their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $55.40.

Get Our Latest Analysis on PTHS

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE lifted its holdings in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 59.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,919 shares of the company’s stock after acquiring an additional 4,819 shares during the period. Pale Fire Capital SE owned approximately 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. 77.96% of the stock is currently owned by institutional investors and hedge funds.

Pelthos Therapeutics Company Profile

(Get Free Report)

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.